Investors want proof AI will aid drug discovery. Evidence may come in the second half
Nvidia is a fan of Recursion Pharmaceuticals. Data expected from the company will help determine valuations for stocks using AI
Read MoreNvidia is a fan of Recursion Pharmaceuticals. Data expected from the company will help determine valuations for stocks using AI
Read MoreAs small-cap stocks take center stage, these names with high liquidity could be worth taking a look at, Jefferies says.
Read MoreOver the next 12 to 18 months, AI-first drug developers will provide updates on early clinical work that will help
Read More